ibandronic acid has been researched along with Kidney Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Bell, R; Coleman, R; Heidenreich, A | 1 |
2 other study(ies) available for ibandronic acid and Kidney Neoplasms
| Article | Year |
|---|---|
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Managing metastatic bone disease: three case studies.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms, Second Primary; Palliative Care; Prostatic Neoplasms | 2004 |